Clinical efficacy of tigecycline combined with sulbactam in treatment of pulmonary infections caused by pandrug-resistant Acinetobacter baumannii

OBJECTIVE To observe the clinical efficacy of tigecycline combined with sulbactam in treatment of pulmonary infections caused by pandrug-resistant Acinetobacter baumannii.METHODS A total of 21cases of pulmonary infections caused by pandrug-resistant A.baumannii,who were treated in the hospital from Apr 2012 to Apr 2013,were enrolled in the study and were randomly divided into the carbapenems group(group A),the carbapenems combined with sulbactam group(group B),and the tigecycline combined with sulbactam group(group C),with 7cases in each group;the three groups showed no statistical difference in the age,gender,length of hospital stay,time of use of antibiotics,or underlying diseases;the bacteriological efficacy and the therapeutic effect were observed and compared between the three groups,and the safety was evaluated.RESULTS The clinical cure rate was 42.86% in the tigecycline combined with sulbactam group,0 in the carbapenems group,14.28% in the carbapenems combined with sulbactam group;the effective rate was 71.43% in the tigecycline combined with sulbactam group,28.57% in the carbapenems group,42.86% in the carbapenems combined with sulbactam group;the bacterial eradication rate was 66.70% in the tigecycline combined with sulbactam group,28.57% in the carbapenems group,42.86% in the carbapenems combined with sulbactam group,the differences between the three groups were significant.The severe adverse reactions did not occur in the tigecycline combined with sulbactam group.CONCLUSIONThe tigecycline combined with sulbactam can achieve good clinical therapeutic effect on pulmonary infections caused by pandrug-resistant A.baumannii and is worthy to be promoted in the hospital.